Agios Pharmaceuticals, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.5% | +18.2% | -38.5% | +119.4% | +24.9% | +72.3% | -100.0% | +34,288.7% | +88.4% | +36.1% | +48.0% | |
| – | +20.1% | +55.2% | +32.9% | -99.5% | -5.7% | +1,325.4% | +0.0% | -90.9% | +457.7% | -56.2% | +176.6% | |
| – | -9.5% | +18.2% | -38.5% | +116.2% | +25.4% | -116.1% | – | – | +38.2% | +86.7% | +31.5% | |
| – | +41.3% | +55.2% | +32.9% | +16.6% | +20.4% | -48.6% | +21.8% | +8.9% | +3.2% | +4.3% | +11.0% | |
| – | +88.2% | +40.9% | +40.2% | +60.5% | +15.7% | +12.9% | -18.5% | +0.2% | -1.5% | +30.8% | +15.0% | |
| – | +48.8% | +52.3% | +34.3% | +25.2% | +19.2% | -41.6% | +13.4% | +11.7% | +1.8% | +12.1% | +12.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +376.8% | +159.7% | +143.6% | +168.6% | -9.7% | +20.0% | -95.3% | +1,430.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -157.6% | |
| – | – | – | – | – | -145.2% | – | -25,303.1% | – | – | +585.4% | -102.3% | |
| – | – | – | – | – | – | – | – | -114.4% | – | – | -161.3% | |
| – | – | – | – | – | – | – | – | – | – | – | -156.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.